GSA Capital Partners LLP Invests $725,000 in CareDx, Inc. $CDNA

GSA Capital Partners LLP acquired a new position in shares of CareDx, Inc. (NASDAQ:CDNA) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 25,440 shares of the company’s stock, valued at approximately $725,000.

Several other large investors have also bought and sold shares of CDNA. Quarry LP bought a new position in CareDx in the fourth quarter valued at about $25,000. Meeder Asset Management Inc. bought a new position in shares of CareDx in the fourth quarter worth about $79,000. Quantbot Technologies LP bought a new position in shares of CareDx in the third quarter worth about $89,000. CWM LLC boosted its stake in shares of CareDx by 119.1% in the 4th quarter. CWM LLC now owns 7,407 shares of the company’s stock valued at $140,000 after purchasing an additional 4,026 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of CareDx by 120.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after purchasing an additional 4,160 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Craig Hallum upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research report on Monday, August 3rd. Zacks Research upgraded shares of CareDx from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. BTIG Research boosted their target price on shares of CareDx from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, William Blair upgraded shares of CareDx to a “hold” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, CareDx presently has an average rating of “Moderate Buy” and a consensus price target of $47.75.

CareDx Stock Performance

Shares of NASDAQ:CDNA opened at $46.51 on Thursday. The firm has a market cap of $2.41 billion, a PE ratio of 22.47 and a beta of 2.39. The firm’s fifty day moving average is $34.87 and its 200-day moving average is $25.01. CareDx, Inc. has a 52 week low of $11.27 and a 52 week high of $49.76.

CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, July 30th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.23 by $0.14. CareDx had a return on equity of 2.87% and a net margin of 24.23%.The firm had revenue of $131.95 million for the quarter, compared to the consensus estimate of $114.05 million. During the same period in the previous year, the business earned ($0.16) EPS. The business’s quarterly revenue was up 52.2% compared to the same quarter last year. Sell-side analysts forecast that CareDx, Inc. will post 0.47 EPS for the current year.

Insider Buying and Selling

In other news, Director George Bickerstaff sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $46.28, for a total value of $925,600.00. Following the transaction, the director owned 134,061 shares in the company, valued at approximately $6,204,343.08. The trade was a 12.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the completion of the sale, the chief executive officer directly owned 661,959 shares in the company, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 114,936 shares of company stock valued at $3,770,348 over the last three months. 2.40% of the stock is owned by insiders.

CareDx Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.